

Patent Assignment Abstract of Title

NOTE: Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 2

Patent #: 6264922 **Issue Dt:** 07/24/2001 **Application #:** 08948216 **Filing Dt:** 10/09/1997

Inventors: RAY W. WOOD, LAN DECASTRO, H. WILLIAM BOSCH

Title: NEBULIZED AEROSALS CONTAINING NANOPARTICULATE DISPERSIONS

Assignment: 1

Reel/Frame: 010797/0486 **Recorded:** 05/05/2000 **Pages:** 15

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: NANOSYSTEMS, L.L.C. **Exec Dt:** 10/01/1998

Assignee: ELAN CORPORATION, PLC
LINCOLN HOUSE, LINCOLN PLACE
DUBLIN 2, IRELAND

Correspondent: FOLEY & LARDNER
MICHELE M. SCHAFER
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-8696

Assignment: 2

Reel/Frame: 010797/0501 **Recorded:** 05/05/2000 **Pages:** 17

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: ELAN CORPORATION, PLC **Exec Dt:** 10/01/1998

Assignee: ELAN PHARMA INTERNATIONAL LIMITED
WIL HOUSE, SHANNON BUSINESS PARK
SHANNON, CO. CLARE, IRELAND

Correspondent: FOLEY & LARDNER
MICHELE M. SCHAFER
3000 K STREET, N.W.
SUITE 500
WASHINGTON, DC 20007-8696

Search Results as of: 02/03/2004 10:51 AM

FORM PTO-1898 (modified)
(Rev 6-93)

05-23-2000

REC

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

5:500

101364077

-IEET

To the Commissioner of Patents and Trademarks. Please record the attached original documents or copies thereof.

1. Name of conveying party(ies):

NanoSystems, L.L.C.



Additional conveying party(ies) NO

3. Nature of conveyance:

ASSIGNMENT

Execution Date: October 1, 1998

2. Name and address of receiving party(ies):

Elan Corporation, PLC
Lincoln House, Lincoln Place
Dublin 2, IRELAND

Additional name(s) & address(es) attached? NO

4. Application number(s) or patent number(s):

If this is being filed together with a new application, the execution date of the application is: N/A

A. Patent Application Number(s):

08/948,216

B. Patent Number(s):

Additional numbers attached? NO

5. Name and address of party to whom correspondence concerning document should be mailed:

Michele M. Schafer
 FOLEY & LARDNER
 Washington Harbour
 3000 K Street, N.W., Suite 500
 P.O. Box 25696
 Washington, D.C. 20007-8696

6. Total number of applications/patents involved: 1

7. Total fee (37 C.F.R. § 3.41): \$40.00

 Check Enclosed

Charge to deposit account

8. Deposit account number: 19-0741

05-23-2000 JENNIFER 00000072 00948216

DO NOT USE THIS SPACE

01 10581

40.00 0P

9. Statement and signature:

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. The Commissioner is hereby authorized to charge any additional recordation fees which may be required in this matter to the above-identified deposit account.

Michele M. Schafer

Michele M. Schafer

May 5, 2000

Date

Name of person signing

Signature

Total number of pages including cover sheet, attachments, and document: 15

002.297397.1

PATENT
REEL: 010797 FRAME: 0486



ASSET PURCHASE AGREEMENT

by and between

**NANOSYSTEMS L.L.C.,
EASTMAN KODAK COMPANY**

and

ELAN CORPORATION, PLC

Dated as of August 21, 1998

NY1228:97443.11

**PATENT
REEL: 010797 FRAME: 0487**



SCHEDULES TO DISCLOSURE STATEMENT

Schedule 1.1(a)	Equipment
Schedule 1.1(b)	NanoSystems Real Property
Schedule 1.1(c)	NanoSystems Intellectual Property
Schedule 3.8	Capitalization
Schedule 3.10	Absence of Change
Schedule 4.5	Consents
Schedule 4.6(a)	Intellectual Property Infringements
Schedule 4.6(b)	Intellectual Property Restrictions
Schedule 4.8(a)	Material Contracts
Schedule 4.8(b)	Contracts: Breaches/Events
Schedule 4.8(c)	Certain Contracts
Schedule 4.9	Manufacturing Rights
Schedule 4.10	Administrative Actions
Schedule 4.13(a)	Benefit Plans
Schedule 4.13(f)	Payments Resulting from Transactions
Schedule 4.14(b)	Environmental
Schedule 4.17(c)	Commitments Since 12/31/97
Schedule 4.17(g)	Severance Payment
Schedule 4.20	Undisclosed Liabilities
Schedule 4.21	Insurance
Schedule 4.22	Year 2000 Compliance
Schedule 5.2	Commitments Prior to Closing
Schedule 5.5(a)	Severance Plan
Schedule 5.5(b)	Kodak Employee
Schedule 6.1(c)	Consents

EXHIBIT A Warrant Agreement

*Schedule
1.1(c)*

TP

MAY 05 2000

SCHEDULE 1.1.c

Aerosol Systems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1998			
Title of Invention	Country	Patent/Appn. No.	Status
Aerosols Containing Bacteriocides/Nanoparticulate Dispersions	U.S.	Patent No. 5,747,801	Granted
	Canada	Appn. No. 2,213,646	Pending
	Europe	Appn. No. 94903547.1	Pending
	Japan	Appn. No. 6-325798	Pending
Aerosols Containing Nanoparticulates/Dispersion	U.S.	Patent No. 5,747,801	Granted
	Canada	Appn. No. 2,213,634	Pending
	Europe	Appn. No. 94903546.3	Pending
	Japan	Appn. No. 6-325798	Pending
Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulosic Surface Stabilizers and Methods of Making Such Formulations	U.S.	Appn. No. 08/850,602	Pending
	PCT	PCT/US97/14097	Pending
Pharmaceutical Compositions Containing Polyalkylene Block Copolymers Which Gel at Physiological Temperature	U.S.	Patent No. 5,543,118	Granted
	U.S.	Patent No. 5,703,704	Granted
	Canada	Appn. No. 2,213,643	Pending
	Europe	Appn. No. 94907043.1	Pending
	Japan	Appn. No. 6-325803	Pending
Nanoparticles Containing the R(-) Enantiomer of Isoproterenol	U. S.	Patent No. 5,718,919	Granted
Formulations of Oral/Gastrointestinal Therapeutic Agents in Combination with Pharmaceutically Acceptable Clays	U. S.	Patent No. 5,585,108	Granted
Microprecipitation of Nanoparticulate Pharmaceutical Agents	U. S.	Patent No. 5,360,832	Granted
Isolation of Ultra Small Particles	U. S.	Patent No. 5,303,723	Granted
Nanoparticulate Diagnostic Mixed Carbonic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging	U. S.	Patent No. 5,543,332	Granted
	U. S.	Patent No. 5,473,643	Granted
	U. S.	Patent No. 5,373,749	Granted
Iodinated Aryloxy Esters	U. S.	Patent No. 5,122,679	Granted
	U. S.	Patent No. 5,466,413	Granted
	U. S.	Patent No. 5,318,117	Granted
Method of Grinding Pharmaceutical Substances	Argentina	Appn. No. 326,216	Pending
	Australia	Patent No. 660832	Granted
	Canada	Appn. No. 2,107,400	Pending
	Taiwan	Patent No. NI-45476	Granted
	Czech Republic	Appn. No. 91/2277	Pending
	Europe	Appn. No. 93302753.6	Pending
	Finland	Patent/Appn. No. 934320	Pending

SCHEDULE 1.1.c

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents**
August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
<u>Method of Grinding Pharmaceutical Substances</u>	Hungary	Patent No. 215924	Granted
	Japan	Appn. No. 222497/93	Pending
	South Korea	Appn. No. 221647/93	Pending
	Malaysia	Patent No. 51Y-109-215-A	Granted
	Mexico	Appn. No. 33-6443	Pending
	New Zealand	Patent No. 243813	Granted
	Norway	Appn. No. 51-01719	Pending
	Philippines	Appn. No. 81M47638	Pending
	Russia	Patent/Appn. No. 93352890	Pending
	Slovak Republic	Appn. No. PV 1301/93	Pending
	Ukraine	Appn. No. 9320466	Pending
<u>Indispersible Nanoparticulate Film Matrices With Protective Overcoat</u>	Venezuela	Appn. No. 1484/93	Pending
	U.S.	Patent No. 5,571,713	Granted
	Canada	Appn. No. 2,312,803	Pending
	Europe	Appn. No. 94704612.7	Pending
	Japan	Appn. No. 6-3213046	Pending
<u>Iodinated Aromatic Compounds</u>	U.S.	Patent No. 5,314,107	Granted
<u>Method to Reduce Particle Size Growth During Lyophilization</u>	U.S.	Patent No. 5,302,401	Granted
<u>Iodinated Benzoyl Acetals and Ketols for X-Ray Imaging</u>	U.S.	Patent No. 5,330,739	Granted
<u>Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids</u>	U.S.	Patent No. 5,371,336	Granted
	U.S.	Patent No. 5,360,931	Granted
	Canada	Appn. No. 2,307,304	Pending
	Europe	Appn. No. 93004532.3	Pending
	Japan	National Phase Appn. of PCT/US96/01433	Pending
<u>Use of Non-Ionic Blood Pool Modifiers to Minimize Nanoparticle Aggregation During Sterilization</u>	U.S.	Patent No. 5,346,762	Granted
<u>The Use of Tyloxapol as a Nanoparticle Stabilizer and Dispersant</u>	U.S.	Patent No. 5,419,524	Granted
	Argentina	Appn. No. 126,159	Pending
	Australia	Patent No. 2,433,648	Granted
	Canada	Appn. No. 2,406,192	Pending
	Taiwan	Appn. No. 12105788	Pending
	Europe	Appn. No. 93243351.7	Pending
	Poland	Pol/Appn. No. 10/21093	Pending
	Hungary	Pol/Appn. No. 93101104	Pending
	Israel	Appn. No. 93/107874	Pending
	Japan	Appn. No. 21079943	Pending
	South Korea	Appn. No. 22700243	Pending

SCHEDULE I.I.c

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents**
August 26, 1998

Title of Invention	Country	Patent/Appn. No.	Status
The Use of Tycampol as a Nanoparticle Stabilizer and Dispenser	Malaysia	Appn. No. PI 9302636	Granted
	New Zealand	Patent No. 248726	Granted
	Norway	Appn. No. P334434	Pending
	Philippines	Patent No. 25937	Granted
	Russia	Appn. No. 93054941.00	Pending
	Slovak Republic	Appn. No. PV 1424-93	Pending
	Ukraine	Appn. No. 91001342	Pending
	U.S.	Patent No. 5,760,478	Granted
Industied Arylony Carbamides	Argentina	Appn. No. 121,629	Pending
	Australia	Patent No. 643442	Granted
	Canada	Appn. No. 2,167,387	Pending
	Taiwan	Patent No. NJ-072317	Granted
	Hungary	Pat./Appn. No. P9301475	Hungary
	Ireland	Appn. No. 93/107254	Granted
	Japan	Appn. No. 210511293	Pending
	South Korea	Appn. No. 93/211154	Pending
	Malaysia	Patent No. MY-189,200A	Granted
	New Zealand	Patent No. 241431	Granted
	Philippines	Patent No. 30136	Granted
	Ukraine	Appn. No. 93/1420	Pending
	Venezuela	Patent No. 134403	Granted
X-Ray Contrast Compositions Useful in Medical Imaging	U.K.	Patent No. 5,451,393	Granted
	U.K.	Patent No. 5,311,767	Granted
	Europe	Appn. No. 92300732.4	Pending
Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization	U.S.	Patent No. 5,332,459	Granted
	Argentina	Appn. No. 121,525	Pending
	Taiwan	Appn. No. 81109723	Pending
	Japan	Appn. No. 21647293	Pending
	South Korea	Appn. No. 93/21383	Pending
	Malaysia	Appn. No. PI 9302199	Pending
	Mexico	Appn. No. 937381	Pending
	New Zealand	Patent No. 238116	Granted
	Philippines	Appn. No. 47231	Pending
	Russia	Appn. No. 93/53813	Pending
	Slovak Republic	Appn. No. PV 141683	Pending
Formulations of Nanoparticulate Naphthalene Tablets	U.S.	Appn. No. 08/800,006	Pending
	PCT	PCT/US97/01358	Pending

SCHEDULE 1.1.c

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1998			
Title of Invention	Country	Patent/Appn. No.	Status
Addition of Intravenously Administered Nanoparticulate Formulation Induced Adverse Physiological Reactions	U.S.	Appn. No. 01/694,754	Pending (Allowed)
	Canada	Based on PCT/US96/15300	Pending
	Europe	Based on PCT/US96/15300	Pending
	Japan	Based on PCT/US96/15300	Pending
Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles	U.S.	Patent No. 5,343,113	Granted
Butylene Oxide-Ethylenimine Block Copolymer Surfactants as Stabilizer Coatings for Nanoparticle Compositions	U.S.	5,387,143	Granted
	Argentina	Appn. No. 132,213	Pending
	Australia	Appn. No. 19940793	Pending
	Canada	Appn. No. 2,193,391	Pending
	Taiwan	Appn. No. 1400107531	Pending
	Europe	Appn. No. 939104810	Pending
	Finland	Pat. Appn. No. PI 93214	Pending
	Israel	Patent/Appn. No. 94/14354	Pending
	Japan	Appn. No. 30110374	Pending
	Malaysia	Appn. No. PI 9301774	Pending
	Norway	Appn. No. P 94 5415	Pending
	Philippines	Appn. No. 30408	Pending
	Venezuela	Appn. No. 93/1026	Pending
Method of Grinding Pharmaceutical Substances	U.S.	Appn. No. 08481,319	Pending (Allowed)
	Argentina	Appn. No. 131,311	Pending
	Canada	Appn. No. 2,190,946	Pending
	Taiwan	Appn. No. 84104440	Pending
	Europe	Appn. No. 939102354	Pending
	Israel	Appn. No. 94/113632	Allowed
	Japan	Appn. No. 304103293	Pending
	Malaysia	Appn. No. PI 9301374	Pending
	Philippines	Appn. No. 30573	Pending
	Venezuela	Appn. No. 93S3-93	Pending
Nanoparticulate Diagnostic Devices as X-Ray/Contrast Agents for Blood Pool and Lymphatic System Imaging	U.S.	Patent No. 5,300,204	Granted
Method of Preparing Stable Drug Nanoparticles	U.S.	Patent No. 5,334,270	Granted
Solubilized Non-Ionic Block Copolymer Surfactants as Stabilizer Coatings for Nanoparticle Compositions	U.S.	Patent No. 5,369,441	Granted
Iodinated Aromatic Propenamedicines	U.S.	Patent No. 5,264,810	Granted
	U.S.	Patent No. 5,338,404	Granted
Iodinated Areykary Resins	U.S.	Patent No. 5,408,113	Granted

SCHEDULE 1.1.c

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents**
August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Novel Purpose Diagnostic/Therapeutic Agent Containing a Tri-Lactamized Bocanyl Group Attached to a Cysteamine	U.S.	Patent No. 5,645,330	Granted
Improved Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents	U.S.	Patent No. 5,625,911	Granted
Non-Particulate Iodopamide Derivatives for Use as X-Ray Contrast Agents	U.S.	Appn. No. 08/815,346	Pending
Non-Particulate Diagnostic Diaminopyridine Esters and X-Ray Contrast Agents for Blood Pool and Hepatic System Imaging	U.S.	Patent No. 5,521,218	Granted
Oral Non-Salt Formulations Stabilized by Ionic and Antiseptic Stabilizers	U.S.	Patent No. 5,313,328	Granted
Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents	U.S.	Patent No. 5,301,492	Granted
Novel Formulations for Nonparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-Ionic Surfactants	U.S.	Patent No. 5,324,552	Granted
The use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Stabilization	U.S.	Patent No. 5,467,710	Granted
Use of Charged Phospholipids to Reduce Particle Aggregation	U.S.	Patent No. 5,470,383	Granted
Process of Preparing Therapeutic Compositions Containing Nanoparticles	U.S.	Patent No. 5,310,118	Granted
Nonparticulate NSAID Formulations	U.S.	Patent No. 5,318,738	Granted
	Canada	Appn. No. 2,212,778	Pending
	Europe	Appn. No. 96903181.3 (to be completed in all EP designated countries)	Pending (Allowed)
	Japan	Appn. No. 1-574368	Pending
Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents	U.S.	Patent No. 5,340,931	Granted
Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents Using Surface Active Material Derived From Similar Pharmaceutical Agents	U.S.	Patent No. 5,718,842	Granted
Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers	U.S.	Patent No. 5,663,331	Granted
Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents with Crystal Growth Modifiers	U.S.	Patent No. 5,662,883	Granted
Surface Modified Drug Nanoparticles	U.S.	Patent No. 5,143,634	Granted
	Argentina	Appn. No. 92/21681	Pending

SCHEDULE 1.1.c

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents**
August 28, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Surface Modified Drug Nanoparticles			
	Australia	Patent No. 634836	Granted
	Canada	Appn. No. 255432	Pending
	Chile	Appn. No. 52074	Pending
	Colombia	Patent No. 24619	Granted
	Europe	Appn. No. 91258135.2 Publication No. 499299	Pending
	Finland	Pat/Appn. No. 510321	Pending
	Hungary	Pat/Appn. No. 55-224	Pending
	Ireland	Appn. No. 92-0217	Pending
	Israel	Patent/Appn. No. 166754	Granted
	Japan	Appn. No. 52/11228	Pending
	South Korea	Appn. No. 92-1577	Pending
	Malaysia	Patent No. MY-161134-A	Granted
	Mexico	Patent No. 176143	Granted
	New Zealand	Patent No. 241362	Granted
	Norway	Appn. No. 52-00134	Allowed
	Philippines	Patent No. 25059	Granted
	Russia	Pat. No. 2034153	Granted
	Singapore	Appn. No. 9403561-J	Pending
	Taiwan	Patent No. NI-671112	Granted
Surface Modified Anticancer Nanoparticles			
	UK	Patent No. 2144181	Granted
	U.S.A.	Patent No. 5,191,142	Granted
	Argentina	Appn. No. 100211,200	Pending
	Australia	Patent No. 674422	Granted
	Canada	Appn. No. 2556142	Pending
	Czech Republic	Appn. No. PV 131693	Pending
	China	Appn. No. 93101850.9	Pending
	Europe	Appn. No. 93201103.1 Publication No. 577213	Pending
	Finland	Pat/Appn. No. 513640	Pending
	Hungary	Pat/Appn. No. 51361917	Pending
	Israel	Patent/Appn. No. 166198	Pending
	Japan	Appn. No. 53/131828	Pending
	South Korea	Appn. No. 53/12247	Pending
	Malaysia	Appn. No. PI 9301273	Pending (Allowed)
	Mexico	Appn. No. 93X1850	Pending
	New Zealand	Patent No. 241362	Granted
	Norway	Appn. No. 53-1403	Pending
	Philippines	Patent No. 30104	Granted
	Russia	Appn. No. 93046216	Pending
	Singapore	Appn. No. 9403603-6	Pending
	Slovak Republic	Pat/Appn. No. PV 0681-73	Pending
	Taiwan	Patent No. NI-779294	Granted
	Uruguay	Appn. No. 93003637	Pending

ISSUING AND GRANTED PATENTS
August 20, 1990

Title of Invention	Country	Patent/Appn. No.	Status
Surface Modified Anticancer Nanoparticles	Venezuela	Pat/Appn. No. 6345-81	Pending
Surface Modified NALD Nanoparticles	U.S.	Patent No. 5,352,160	Granted
	Australia	Patent No. 677713	Granted
	Austria	European Patent No. 644 733	National Registration of EP 644 733
	Belgium	European Patent No. 644 733	National Registration of EP 644 733
	Canada	Appn. No. 2118317	Pending
	Denmark	European Patent No. 644 733	National Registration of EP 644 733
	Europe	European Patent No. 644 733	Granted
	France	European Patent No. 644 733	National Registration of EP 644 733
	Germany	European Patent No. 644 733	National Registration of EP 644 733
	Greece	European Patent No. 644 733	National Registration of EP 644 733
	Hungary	Pat/Appn. No. 34-3543	Pending
	Ireland	European Patent No. 644 733 Irish Patent No. 1072603	Granted
	Italy	European Patent No. 644 733	National Registration of EP 644 733
	Japan	Appn. No. 54/301313	Pending
	Luxembourg	European Patent No. 644 733	National Registration of EP 644 733
	Moscow	European Patent No. 644 733	National Registration of EP 644 733
	Mexico	Appn. No. 83-3433	Pending
	Netherlands	European Patent No. 644 733	National Registration of EP 644 733
	Portugal	European Patent No. 644 733	National Registration of EP 644 733
	Spain	European Patent No. 644 733	National Registration of EP 644 733

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents
August 20, 1998**

Title of Invention	Country	Patent/Appn. No.	Status
1. Modified NSAID Nanoparticles	Sweden	European Patent No. 644 735	National Registration of EP 644 735
	Switzerland	European Patent No. 644 735	Granted
	United Kingdom	European Patent No. 644 735	National Registration of EP 644 735
2. Novel Adhesive Within the GI-Tract Nanoparticles Stabilized by High Molecular Weight, Linear Poly(alkylene ether) Polymers	U.S.	Patent No. 5,385,379	Granted
3. Novel Imaging X-Ray Contrast Agents	U.S.	Patent No. 5,371,730	Granted
4. Coated Surfaces for Nanocrystals	U.S.	Patent No. 5,353,318	Granted
5. Methods of Oral Gastrointestinal Imaging X-Ray Contrast Agents in Combination with Pharmaceutically Acceptable Carriers	U.S.	Patent No. 5,464,440	Granted
6. Naphthalene with Hydroxypropyl Esters as a Dispersion Stabilizer	U.S.	Patent No. 5,391,436	Granted
7. Novel Mono-5-Substituted-Amino- Benzilate Esters Useful as X-Ray Contrast Agents for Medical Diagnostic Imaging	U.S.	Patent No. 5,370,156	Granted
8. Novel (Alkylene) Amino)-3,4,5- Substituted Esters	U.S.	Patent No. 5,303,916	Granted
9. A New Method of Grinding Pharmaceutical Substances	U.S.	Patent No. 5,716,348	Granted
International Applications			
10. Novel Alkylphenol Esters as Novel X-Ray Contrast Agents	Argentina	Appln. No. 331,937	Pending
	Canada	Appln. No. 2,190,134	Pending
	Taiwan	Appln. No. 14101642	Pending
	Europe	Appln. No. 95919082.0	Pending
	Israel	Appln. No. 113031	Pending
	Japan	Appln. No. 95/250017	Pending
	Malaysia	Appln. No. P1 9501573	Pending
	Philippines	Appln. No. 95/50574	Pending
	Venezuela	Appln. No. 03/34-83	Pending
11. Novel Alkylphenol Esters as Novel X-Ray Contrast Agents	U.S.	Appln. No. 08/677,708	Pending
12. Novel 1-Amino-Triiodophenyl Esters as X- Ray Contrast Agents	U.S.	Patent No. 5,661,114	Granted September 16, 1997
13. Novel Copolymers and a Process for Preparing Them	U.S.	Appln. No. 08/416,119	Pending
	Argentina	Appln. No. 331,133	Pending
	Canada	Appln. No. 2,207,381	Pending
	Taiwan	Appln. No. 1400162752	Pending
	Europe	Appln. No. 95904320.4	Pending
	Israel	Appln. No. 94/011314	Pending

SCHEDULE 1.1.c

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents**
August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Number 1: Copolymers and a Process for Making Them	Europe	National Phase of PCT/EP94/04261	Pending
	Japan	National Phase of PCT/JP94/04261	Pending
	Malaysia	Appln. No. PI 5300032	Pending
	Mexico	Appln. No. 31100	Pending
	Philippines	Appln. No. 50330	Pending
	Great Britain	Patent No. 2243977	Granted
Number 2: Rhombohedral Crystalline Form of Triamcinolone Acetonide, Compositions Comprising the Rhombohedral Crystalline Form of Triamcinolone Acetonide, Methods of Making and Using Such Compositions, Methods of Making Nanocrystalline Compositions of Tetragonal Crystalline Form of Triamcinolone Acetonide and Stable Formulations of Naproxen	Venezuela	Appln. No. 53/114	Pending
	U.S.	Appln. No. 08/911,281	Pending
		Appln. No. Unknown (filed on August 13, 1998)	Pending



the Acquired Assets are subject, other than in the case of clauses (ii) and (iii) any conflict, breach, default, termination, cancellation, acceleration, loss, violation or Encumbrance which, individually or in the aggregate, would not have a Material Adverse Effect or materially impair or delay Seller's ability to perform its obligations hereunder.

4.4 Binding Effect. This Agreement constitutes a valid and legally binding obligation of Seller enforceable in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors' rights and to general equity principles.

4.5 Consents and Approvals. Except as required by the H-S-R Act, no consent, approval, waiver or authorization is required to be obtained by Seller from, and no notice or filing is required to be given by Seller to or made by Seller with, any Federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by Seller of this Agreement other than those the failure of which to obtain, give or make would not have a Material Adverse Effect or materially impair or delay the ability of Seller to effect the Closing.

4.6 Intellectual Property. To the best Knowledge of Seller, Seller owns or has the right to use all of the Intellectual Property included in the Acquired Assets. The Intellectual Property included in the Acquired Assets constitutes all of the Intellectual Property necessary to conduct the Business as currently conducted. Schedule 1.1(e) contains a worldwide list of all patents, trade names, trademarks and service marks, and applications for the foregoing owned or possessed by the Seller and true and complete copies of all such materials have been made available to Buyer. Seller has taken all action reasonably necessary to establish and protect its interest in and to the NanoSystems Intellectual Property. To the Knowledge of Seller, (i) Seller's products do not infringe on or otherwise violate the Intellectual Property of any other Person, and (ii) no Person is challenging, infringing or otherwise violating the NanoSystems Intellectual Property. Except as set forth in the Contracts listed on Schedule 4.6(b), there is no limitation on Seller's ability or right to license any of the NanoSystems Intellectual

Property to any Person. All issued patents and registered trademarks and service marks owned by Seller are recorded on the public record solely in the name of Seller.

4.7 Title and Condition of Tangible Property. Seller has good title to, or a valid and binding leasehold interest in, the tangible property included in the Acquired Assets, free and clear of all Encumbrances, except: (i) Liens for Taxes, Assessments and other governmental charges (a) not yet due and payable or (b) being contested in good faith by appropriate proceedings and for which adequate reserves have been established, and (ii) Encumbrances which, individually or in the aggregate, would not have a Material Adverse Effect. Upon the consummation of the transactions contemplated hereby, assuming Buyer is a bona fide purchaser for value with no knowledge of an adverse claim, Buyer will acquire good title to the tangible property included in the Acquired Assets, free and clear of all Encumbrances, except for the exceptions in clauses (i) and (ii) of this Section 4.7. The tangible property included in the Acquired Assets is in all material respects in good working condition, ordinary wear and tear excepted.

4.8 Contracts.

(a) Schedule 4.8(a) sets forth a list, as of the date hereof, of each Contract that is material to Seller. Each such Contract is a valid and binding agreement of Seller or its Affiliates and is in full force and effect.

(b) To the Knowledge of Seller, there has been no material breach or default under any Contract listed on Schedule 4.8(a) except for defaults that have been cured or waived and breaches and defaults which are not material. No event has occurred with respect to Seller which, with notice or lapse of time or both, would constitute a material breach, violation or default, or give rise to a right of termination, cancellation, foreclosure, imposition of a lien or penalty, prepayment or acceleration under any such Contract.

(c) Seller is not a party to any Contract in any of the following categories:

NY12928:97443 11

-18-



ASSIGNMENT OF INTELLECTUAL PROPERTY OTHER THAN PATENTS

KNOW ALL PERSONS BY THESE PRESENTS that in connection with the Asset Purchase Agreement, dated as of August 21, 1998 (the "Agreement"), by and among Elan Corporation, plc, a public limited company organized under the laws of Ireland ("Buyer"), NanoSystems L.L.C., a limited liability company organized under the laws of the State of Delaware ("Seller"), and Edman Kodak Company, a New Jersey corporation (capitalized terms not defined herein shall have the meaning ascribed to them in the Agreement), Seller, for good and valuable consideration, receipt of which is hereby acknowledged, hereby ASSIGNS to Buyer all of Seller's right, title and interest in and to all Intellectual Property included in the Acquired Assets (other than the rights to develop and commercialize a nanocrystal version of Paclitaxel) in accordance with the terms of the Agreement.

IN WITNESS WHEREOF, Seller has caused this instrument to be executed by its duly authorized officer on the 1st day of October, 1998.

NANOSYSTEMS L.L.C.

By: Particular Prospects Corp.,
Member

By: Akram Sandhu
Name: Akram Sandhu
Title: Vice President

NY12529-199E203

Received 04-22-01 11:05am
RECORDED: 05/05/2000

From-

To-FOLEY AND LARDNER PATENT Page 05
REEL: 010797 FRAME: 0500